Bevacizumab in the therapy for refractory metastatic colorectal cancer
Mary F MulcahyNorthwestern University, Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Chicago IL, USAAbstract: Colorectal cancer is the second most common cause of cancer related deaths in the United States. Recent developments have led to prolonged survival with the u...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2008
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/c87ea3c9c05e47798ea5dcaa53730154 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:c87ea3c9c05e47798ea5dcaa53730154 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:c87ea3c9c05e47798ea5dcaa537301542021-12-02T02:35:26ZBevacizumab in the therapy for refractory metastatic colorectal cancer1177-54751177-5491https://doaj.org/article/c87ea3c9c05e47798ea5dcaa537301542008-03-01T00:00:00Zhttp://www.dovepress.com/bevacizumab-in-the-therapy-for-refractory-metastatic-colorectal-cancer-a53https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Mary F MulcahyNorthwestern University, Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Chicago IL, USAAbstract: Colorectal cancer is the second most common cause of cancer related deaths in the United States. Recent developments have led to prolonged survival with the use of sequential lines of chemotherapy agents. The addition of bevacizumab to active chemotherapy has further improved survival when used in the first and second lines of therapy for metastatic colorectal cancer. Evidence supporting the continued use of bevacizumab throughout lines of therapy is accumulating. Clinical trials are underway in which bevacizumab is continued beyond the first line of a chemotherapy and bevacizumab combination regimen. The mechanism by which colorectal cancer may become resistant to bevacizumab is poorly understood. Molecular and biochemical correlates which may identify bevacizumab resistance are an important component in the design of these clinical trials.Keywords: colorectal cancer, bevacizumab, refractory Mary F MulcahyDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 1, Pp 53-59 (2008) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine (General) R5-920 |
| spellingShingle |
Medicine (General) R5-920 Mary F Mulcahy Bevacizumab in the therapy for refractory metastatic colorectal cancer |
| description |
Mary F MulcahyNorthwestern University, Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Chicago IL, USAAbstract: Colorectal cancer is the second most common cause of cancer related deaths in the United States. Recent developments have led to prolonged survival with the use of sequential lines of chemotherapy agents. The addition of bevacizumab to active chemotherapy has further improved survival when used in the first and second lines of therapy for metastatic colorectal cancer. Evidence supporting the continued use of bevacizumab throughout lines of therapy is accumulating. Clinical trials are underway in which bevacizumab is continued beyond the first line of a chemotherapy and bevacizumab combination regimen. The mechanism by which colorectal cancer may become resistant to bevacizumab is poorly understood. Molecular and biochemical correlates which may identify bevacizumab resistance are an important component in the design of these clinical trials.Keywords: colorectal cancer, bevacizumab, refractory |
| format |
article |
| author |
Mary F Mulcahy |
| author_facet |
Mary F Mulcahy |
| author_sort |
Mary F Mulcahy |
| title |
Bevacizumab in the therapy for refractory metastatic colorectal cancer |
| title_short |
Bevacizumab in the therapy for refractory metastatic colorectal cancer |
| title_full |
Bevacizumab in the therapy for refractory metastatic colorectal cancer |
| title_fullStr |
Bevacizumab in the therapy for refractory metastatic colorectal cancer |
| title_full_unstemmed |
Bevacizumab in the therapy for refractory metastatic colorectal cancer |
| title_sort |
bevacizumab in the therapy for refractory metastatic colorectal cancer |
| publisher |
Dove Medical Press |
| publishDate |
2008 |
| url |
https://doaj.org/article/c87ea3c9c05e47798ea5dcaa53730154 |
| work_keys_str_mv |
AT maryfmulcahy bevacizumabinthetherapyforrefractorymetastaticcolorectalcancer |
| _version_ |
1718402374186303488 |